Boehringer Ingelheim’s Jascayd has received European marketing authorisation for idiopathic [...]

Qureight has raised $20 million in a Series B financing [...]

spliesense-cystic-fibrosis-foundation-spl84-phase2b SpliSense has secured up to $13 million in funding [...]

Tozorakimab has met its primary endpoint in two replicate Phase [...]

Qureight, a techbio company advancing the understanding of lung and [...]

Qureight’s deep-learning biomarkers confirm representativeness of Insilico’s Phase 2a IPF [...]